Psychopharmacology

  • Silvia S. Gratz
  • George M. Simpson
Part of the Critical Issues in Psychiatry book series (CIPS)

Abstract

Research in psychopharmacology is both blessed and plagued by its history. In 1949, the psychiatrist John Cade discovered the antimanic properties of lithium when he hypothesized that manic-depressive illness is analogous to thyrotoxicosis-myxedema. Eventually, he determined that lithium made guinea pigs lethargic and manic patients calm. Within a 2-year span (1950–1951), this discovery generated three Australian and three French studies. Despite this initial enthusiasm with lithium, this event did not launch psychopharmacology as an important therapeutic field. The French surgeon Henri Laborit’s keen observation that chlorpromazine (CPZ) nullified preoperative anxiety, mitigated surgical stress, and thereby eliminated its postoperative consequences, led him with dynamic persuasion to convince early psychiatrists to give CPZ for psychotic states. Colonel Paraire, a psychiatrist and Laborit’s colleague, has been credited with the first report and publication on the therapeutic effects of intravenous (IV) CPZ in a manic patient; this article appeared in the Annales Médico-Psycholigiques in March, 1952. Delay and Deniker’s study of 38 subjects, although totally lacking in methodological rigor by modern day standards (an open study with mixed diagnoses without controls and rating scales), nevertheless, resulted in one of the notable therapeutic advances of the century, provoked research throughout the world, and stirred the ambitions of pharmaceutical manufacturers.

Keywords

Schizophrenic Patient Panic Disorder Clinical Psychiatry Trigeminal Neuralgia Extrapyramidal Side Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baird, E. S., & Hailey, D. M. (1972). Delayed recovery from a sedative: Correlation of the plasma levels of diazepam with clinical effects after oral and intravenous administration. British Journal of Anesthesia, 44, 803–807.CrossRefGoogle Scholar
  2. Balster, R. L., & Woolverton, W. L. (1982). Intravenous buspirone self-administration in rhesus monkeys. Journal of Clinical Psychiatry, 43, 34–37.PubMedGoogle Scholar
  3. Bouchard, R. H., Pourcher, E., & Vincent, P. (1989). Fluoxetine and extrapyramidal side effects [Letter to the editor]. American Journal of Psychiatry, 146, 1352–1353.Google Scholar
  4. Brod, T. M. (1989). Fluoxetine and extrapyramidal side effects [Letter to the editor]. American Journal of Psychiatry, 146, 1353.Google Scholar
  5. Burlington, D. B., & Gubish, E. R. (1987). Review of investigational biological products by the United States Food and Drug Administration. Journal of Clinical Research and Drug Development, 1, 143–152.Google Scholar
  6. Burt, C. G., Gordon, W. F., Holt, N. F., & Hordern, A. (1962). Amitriptyline in depressive states: A controlled trial. Journal of Mental Science, 108, 711–730.PubMedGoogle Scholar
  7. Caldwell, A. E. (1978). History of psychopharmacology. In W. G. Clark & J. del Giudice (Eds.), Principles of psychopharmacology (pp. 9–40). New York: Academic Press.Google Scholar
  8. Cohen, B. J., Mahelsky, M., & Adler, L. (1990). More cases of SIADH with fluoxetine. American Journal of Psychiatry, 147, 948–949.PubMedGoogle Scholar
  9. Cole, J. O., Orzack, M. H., Beake, B., Bird, M., & Bar-Tal, Y. (1982). Assessment of the abuse liability of buspirone in recreational sedative users. Journal of Clinical Psychiatry, 34, 69–74.Google Scholar
  10. Delay, J., & Deniker, P. (1952). 38 cas de psychosis traités par la cure prolongée et continué de 4568 R. P. Annales Médico-Psychologiques, 110, 364.Google Scholar
  11. Frank, E., Kupfer, D. D. J., Perel, J. M., Cornes, C., Jarrett, D. B., Mallinger, A. G., Thase, M. E., McEachran, A. B., & Grochocinski, V J. (1990). Three-year outcomes for maintenance therapies in recurrent depression. Archives of General Psychiatry, 47, 1093–1099.PubMedCrossRefGoogle Scholar
  12. Freeman, C., & Tyrer, P. (Eds.). (1989). Research methods in psychiatry: A beginners guide. London: Gaskell.Google Scholar
  13. Ghoneim, M. M., Korttila, K., & Chiang, C. K. (1981). Diazepam effects and kinetics in Caucasians and Orientals. Clinical Pharmacology and Therapy, 29, 749–756.CrossRefGoogle Scholar
  14. Glassman, A. H., Perel, J. M., Shostak, M., Kantor, S. J., & Fleiss, J. L. (1977). Clinical implications of imipramine plasma levels for depressive illness. Archives of General Psychiatry, 34, 197–204.PubMedCrossRefGoogle Scholar
  15. Goff, D. C., Brotman, A. W., Waites, M., & McCormick, S. (1990). Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. American Journal of Psychiatry, 147, 492–494.PubMedGoogle Scholar
  16. Greenblatt, D. J., Shader, R. I., & MacLeod, S. M. (1978). Clinical pharmacokinetics of chlordiazepoxide. Clinical Pharmacokinetics, 3, 381–394.PubMedCrossRefGoogle Scholar
  17. Griffith, J. D., Jasinski, D. R., Casten, G. P., & McKinney, G. R. (1986). Investigation of the abuse liability of buspirone in alcohol-dependent patients. American Journal of Medicine, 80, 30–35.PubMedCrossRefGoogle Scholar
  18. Hammer, W., & Sjoqvist, F. (1967). Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Science, 6, 1895–1903.CrossRefGoogle Scholar
  19. Hansen, T. E., Dieter, K., & Keepers, G. A. (1990). Interaction of fluoxetine and pentazocine [Letter to the editor]. American Journal of Psychiatry, 147, 949–950.PubMedGoogle Scholar
  20. Hillestad, L., Hansen, T., & Melsom, H. (1974). Diazepam metabolism in normal man: Serum concentrations and clinical effects after intravenous, intramuscular, and oral administration. Clinical Pharmacology and Therapy, 16, 479–484.Google Scholar
  21. Hordern, A., Holt, N. F., Burt, C. G., & Gordon, W. F. (1963). Amitriptyline in depressive states: Phenomenology and prognostic considerations. British Journal of Psychiatry, 109, 815–825.PubMedCrossRefGoogle Scholar
  22. Hwang, A. S., & Magraw, R. M. (1989). Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine [Letter to the editor]. American Journal of Psychiatry, 146, 399.PubMedGoogle Scholar
  23. Jefferson, T. W., Greist, J. H., Ackerman, D. L., & Carroll, J. A. (1987). Lithium encyclopedia for clinical practice (2nd ed.). Washington, DC: American Psychiatric Press.Google Scholar
  24. Kocsis, J. H., & Frances, A. J. (1987). A critical discussion of DSM-III dysthymic disorder. American Journal of Psychiatry, 144, 1534–1542.PubMedGoogle Scholar
  25. Kyriakopoulos, A. A., Greenblatt, D. J., & Shader, R. I. (1978). Clinical pharmacokinetics of lorazepam: A review. Journal of Clinical Psychiatry, 39, 16–23.PubMedGoogle Scholar
  26. Liebowitz, M. R., Quitkin, F. M., Stewart, J. W., McGrath, P. J., Harrison, W. M., Markowitz, J. S., Rabkin, J. G., Tricamo, E., Goetz, D. M., & Klein, D. F. (1988). Antidepressant specificity in atypical depression. Archives of General Psychiatry, 45, 129–137.PubMedCrossRefGoogle Scholar
  27. Lipinski, J. E., & Mallya, G., Zimmerman, P., & Pope, H. (1989). Fluoxetine-induced akathisia: Clinical and theoretical implications. Journal of Clinical Psychiatry, 50, 339–342.PubMedGoogle Scholar
  28. Lusznat, R. M., Murphy, D. P., & Nunn, C. M. H. (1988). Carbamazepine vs. lithium in the treatment and prophylaxis of mania. British Journal of Psychiatry, 153, 198–204.PubMedCrossRefGoogle Scholar
  29. Marwick, C. (1985). FDA prepares to meet regulatory challenges of the 21st century. Journal of the American Medical Association, 254, 2189–2193, 2199-2201.PubMedCrossRefGoogle Scholar
  30. Miller, H. I., & Young, F. E., (1989). The drug approval process at the Food and Drug Administration. Archives of Internal Medicine, 149, 655–657.PubMedCrossRefGoogle Scholar
  31. Moskowitz, H., & Smiley, A. (1982). Effects of chronically administered buspirone and diazepam in driving-related skills performance. Journal of Clinical Psychiatry, 34, 45–55.Google Scholar
  32. Okuma, T., Inanga, K., Otsuki, S., Keisuke, S., Takahashi, R., Hazama, H., Mori, A., & Watanabe, S. (1981). A preliminary double-blind study of the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology, 73, 95–96.PubMedCrossRefGoogle Scholar
  33. Paykel, E. S., Freeling, P., & Hollyman, J. A. (1988). Are tricyclic antidepressants useful for mild depression? Pharmacopsychiatry, 21, 15–18.PubMedCrossRefGoogle Scholar
  34. Perse, T. L., Greist, J. H., Jefferson, J. W., Rosenfeld, R., & Dar, R. (1987). Fluvoxamine treatment of obsessive-compulsive disorder. American Journal of Psychiatry, 144, 1543–1548.PubMedGoogle Scholar
  35. Placidi, G. E., Lenzi, A., Lazzerini, E., Cassano, G. B., & Akiskal, H. S. (1986). The comparative efficacy and safety of carbamazepine versus lithium: A randomized, double-blind 3 year trial in 83 patients. Journal of Clinical Psychiatry, 47, 490–494.PubMedGoogle Scholar
  36. Prien, R. F., & Gelenberg, A. J. (1989). Alternatives to lithium for preventive treatment of bipolar disorder. American Journal of Psychiatry, 146, 840–848.PubMedGoogle Scholar
  37. Prien, R. F., Kupfer, D. J., Mansky, P A., Small, J. G., Tuason, V B., Voss, C. B., & Johnson, W. E. (1984). Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders: A report of the NIMH collaborative study group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Archives of General Psychiatry, 41, 1096–1104.PubMedCrossRefGoogle Scholar
  38. Pry-Roberts, C., & Hug, C. C. (Eds.). (1984). Pharmacokinetics of anesthesia. Cambridge, MA: Blackwell Scientific Publications.Google Scholar
  39. Quitkin, E M., Stewart, J. W., McGrath, P. J., Liebowitz, M. R., Harrison, W. M., Tricamo, E., Klein, D. E., Rabkin, J. G., Markowitz, J. S., & Wager, S. G. (1988). Phenelzine versus imipramine in the treatment of probable atypical depression: Defining syndrome boundaries of selective MAOI responders. American Journal of Psychiatry, 145, 306–311.PubMedGoogle Scholar
  40. Quitkin, F. M., McGrath, P. J., Stewart, J. W., Harrison, W., Wager, S. G., Nunes, E., Rabkin, J. G., Tricamo, E., Markowitz, J., & Klein, D. F. (1989). Phenelzine and imipramine in mood reactive depressives. Archives of General Psychiatry, 46, 787–793.PubMedCrossRefGoogle Scholar
  41. Quitkin, F. M., McGrath, P. J., Stewart, J. W., Harrison, W., Tricamo, E., Wager, S. G., Ocepek-Welikson, K., Nunes, E., Rabkin, J. G., & Klein, D. F. (1990). Atypical depression, panic attacks, and response to imipramine and phenelzine. Archives of General Psychiatry, 47, 935–941.PubMedCrossRefGoogle Scholar
  42. Riblet, L. A., Taylor, D. P., Eison, M. S., & Stanton, H. C. (1982). Pharmacology and neurochemistry of buspirone. Journal of Clinical Psychiatry, 43 (Sec. 2), 11–16.PubMedGoogle Scholar
  43. Riblet, L. A., Eison, A. S., Eison, M. S., Taylor, D. P., Temple, D. L., & VanderMaelan, C. P. (1984). Neuropharmacology of buspirone. Psychopathology, 17 (Suppl. 3), 69–78.PubMedCrossRefGoogle Scholar
  44. Rowland, M., & Tozer, T. N. (1989). Clinical pharmacokinetics. Philadelphia: Lea & Febiger.Google Scholar
  45. Sheehan, D. V., Raj, A. B., Sheehan, H., & Soto, S. (1990). Is buspirone effective for panic disorder? Journal of Clinical Psychopharmacology, 10, 3–11.PubMedCrossRefGoogle Scholar
  46. Simpson, G. M., Lee, J. H., Cuculic, Z., & Kellner, R. (1976). Two dosages of imipramine in hospitalized endogenous and neurotic depressives. Archives of General Psychiatry, 33, 1093–1102.PubMedCrossRefGoogle Scholar
  47. Simpson, G. M., Yadalam, K. G., Stephanos, M. J., Lo, E. S., & Cooper, T. B. (1990). Single dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration. Journal of Clinical Psychopharmacology, 10, 417–421.PubMedCrossRefGoogle Scholar
  48. Spiker, D. G., Weiss, J. C., Dealy, R. S., Griffin, S. J., Hanin, L., Neu, J. E., Perel, J. M., Rossi, A. J., & Soloff, P. H. (1985). The pharmacological treatment of delusional depression. American Journal of Psychiatry, 142, 430–436.PubMedGoogle Scholar
  49. Spriet, A., & Simon, P (1985). Methodology of clinical trials. Paris, France: Karger.Google Scholar
  50. Tate, J. L. (1989). Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine [Letter to the editor]. American Journal of Psychiatry, 146, 399–400.PubMedGoogle Scholar
  51. Thoren, P., Asberg, M., Cronholm, B., Jornestedt, L., & Traskman, L. (1980). Clomipramine treatment of obsessive-compulsive disorder: 1. A controlled clinical trial. Archives of General Psychiatry, 37, 1281–1285.PubMedCrossRefGoogle Scholar
  52. Turner, S. M., Jacob, R. G., Beidel, D., & Himmelhoch, J. (1985). Fluoxetine treatment of obsessive-compulsive disorder. Journal of Clinical Psychopharmacology, 5, 207–212.PubMedCrossRefGoogle Scholar
  53. Watkins, S. E., Callender, K., Thomas, D. R., Tidmarsh, S. E., & Shaw, D. M. (1987). The effect of carbamazepine and lithium on remission from affective illness. British Journal of Psychiatry, 150, 180–182.PubMedCrossRefGoogle Scholar
  54. Ziporyn, T. (1985). The Food and Drug Administration: How “those regulations” came to be. Journal of the American Medical Association, 254, 2037–2039, 2043-2046.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1992

Authors and Affiliations

  • Silvia S. Gratz
    • 1
  • George M. Simpson
    • 1
  1. 1.Department of PsychiatryMedical College of Pennsylvania, Eastern Pennsylvania Psychiatric InstitutePhiladelphiaUSA

Personalised recommendations